Trump Fast-Tracks Psychedelic Research for Veterans and Mental Illness

President Donald Trump signed an executive order Saturday aimed at dramatically reshaping how the federal government approaches psychedelic drugs, directing agencies to remove what he called "unnecessary bureaucratic hurdles" blocking research into substances like ibogaine for treating mental health conditions.[1] Flanked by Health and Human Services Secretary Robert F. Kennedy Jr., Surgeon General Dr. Oz, and podcaster Joe Rogan in the Oval Office, Trump framed the action as a lifeline for veterans struggling with severe mental illness. "Our veterans are having a tremendous hard time," Trump said, emphasizing that experimental psychedelic treatments have shown "life changing potential" for those suffering from depression and PTSD.[1] The executive order allocates $50 million in federal funding to match state investments in psychedelic research programs, channeled through the Advanced Research Projects for Health program.[2][4] It directs the Food and Drug Administration to expedite review of psychedelic compounds as "breakthrough drugs" and instructs the Drug Enforcement Administration to establish pathways allowing eligible patients to access investigational psychedelics, including ibogaine, under the Right to Try Act before full FDA approval.[3][5] For drugs that successfully complete Phase 3 clinical trials and receive FDA approval, the order directs the Attorney General to initiate rescheduling reviews so they can be removed from controlled substance lists "very quickly," according to Trump.[3] The order comes amid growing scientific evidence suggesting psychedelics could treat hard-to-address conditions including depression, opioid addiction, and post-traumatic stress disorder.[3] Yet the move represents a reversal of longstanding federal opposition. In 2024, Nora Volkow, director of the National Institute on Drug Abuse—who attended Saturday's signing—said ibogaine was unlikely to gain approval due to cardiac safety concerns, a position the new order is designed to overcome by offering a pathway for first human trials.[3] Leading psychedelic therapy companies emphasized after the announcement that scientific rigor for drug approval would remain unchanged, stressing their commitment to producing strong clinical data.[3] The order also requires the Department of Health and Human Services and FDA to collaborate with the Department of Veterans Affairs and private sector partners to increase clinical trial participation, signaling coordinated federal action on the issue.[5] Texas recently enacted legislation requiring publicly funded ibogaine research, suggesting state-level momentum that the executive order now seeks to leverage through federal matching funds.[4] The executive order represents one of the most significant federal actions on psychedelic drugs in decades, potentially reshaping how the government categorizes and studies substances previously classified as recreational drugs with no medical value. Whether the initiative succeeds depends on FDA review timelines, the quality of clinical trial data, and Congressional willingness to fund the promised research investments in coming fiscal years.